ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 52
- Registration Number
- NCT06406348
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06402513
- Locations
- 🇺🇸
Acpru /Id# 265325, Grayslake, Illinois, United States
A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
- Conditions
- Masseter Muscle Prominence
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 207
- Registration Number
- NCT06399718
- Locations
- 🇺🇸
Westside Aesthetics /ID# 248232, Los Angeles, California, United States
🇺🇸Private Practice - Dr. Steven G. Yoelin /ID# 268046, Newport Beach, California, United States
🇺🇸Pacific Clinical Innovations /ID# 248231, Vista, California, United States
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Sleep DisturbanceAtopic Dermatitis
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT06390722
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
- Conditions
- Masseter Muscle Prominence
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 202
- Registration Number
- NCT06387394
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center /ID# 248218, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona /ID# 248883, Phoenix, Arizona, United States
🇺🇸Skin Care and Laser Physicians of Beverly Hills /ID# 248223, Los Angeles, California, United States
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT06389136
- Locations
- 🇺🇸
Apex Clinical Trials /ID# 263747, Brandon, Florida, United States
🇺🇸Skin Care Research - Tampa /ID# 263750, Tampa, Florida, United States
🇺🇸Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas, United States
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- Conditions
- Recurrent Ovarian CancerFolate Receptor-Alpha Positive
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06365853
- Locations
- 🇺🇸
University of California Los Angeles /ID# 269339, Los Angeles, California, United States
🇺🇸Norton Healthcare /ID# 269070, Louisville, Kentucky, United States
🇺🇸Holy Cross Hospital - Silver Spring /ID# 269344, Silver Spring, Maryland, United States
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06362031
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 89
- Registration Number
- NCT06362044
- Locations
- 🇯🇵
National Cancer Center Hospital East /ID# 265970, Kashiwa-shi, Chiba, Japan
A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Procedure: Breast Milk Sampling
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 10
- Registration Number
- NCT06346288
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill /ID# 263316, Chapel Hill, North Carolina, United States
🇮🇱Shaare Zedek Medical Center /ID# 262738, Jerusalem, Yerushalayim, Israel
🇺🇸UTHealth Women's Research Program - Memorial City /ID# 263939, Houston, Texas, United States